| BID | 4.00 | ASK | 4.48 | ||
| Open | 4.03 | Previous Close | 4.10 | ||
| Pre-Market | - | After-Market | 4.50 | ||
| - - | 0.43 10.57% |
| Target Price | 12.42 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 205.16 | Finscreener Ranking | ★★★★★ 60.87 | |
| Insiders Trans % 3/6/12 mo. | -/-/-100 | Value Ranking | ★★★ 51.36 | |
| Insiders Value % 3/6/12 mo. | -/-/-100 | Growth Ranking | ★★★★ 56.83 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/-100 | Income Ranking | — - | |
| Price Range Ratio 52W % | 12.98 | Earnings Rating | Buy | |
| Market Cap | 105.29M | Earnings Date | 11th May 2023 | |
| Alpha | -0.02 | Standard Deviation | 0.25 | |
| Beta | 1.32 |
Today's Price Range 3.984.24 | 52W Range 3.537.69 | 5 Year PE Ratio Range -2.50-1.20 |
Summary:
Sell
| Technical Indicators: | Sell |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | 0.99% | ||
| 1 Month | -9.15% | ||
| 3 Months | 2.01% | ||
| 6 Months | 0.00% | ||
| 1 Year | -37.50% | ||
| 3 Years | -37.38% | ||
| 5 Years | -85.46% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -134.58 | |||
ROE last 12 Months | -82.32 | |||
ROA (5Y Avg) | -20.82 | |||
ROA last 12 Months | -64.74 | |||
ROC (5Y Avg) | -131.88 | |||
ROC last 12 Months | -66.86 | |||
Return on invested Capital Q | -13.61 | |||
Return on invested Capital Y | -23.16 | |||
Assets Turnover | 0.20 | |||
Receivables Turnover | 5.10 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -1.30 | ||||
| 1.24 | ||||
| 5.91 | ||||
| - | ||||
| -2.70 | ||||
| -2.55 | ||||
| 3.05 | ||||
| 3.46 | ||||
| 78.47M | ||||
| Forward PE | -1.87 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 5.50 | ||||
| 6.20 | ||||
| 0.22 | ||||
| 0.28 | ||||
| -72.40 | ||||
| Leverage Ratio | 1.30 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 27.80 | ||||
| -260.20 | ||||
| -248.30 | ||||
| -305.20 | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 20.85M | ||||
| 0.81 | ||||
| 38.34 | ||||
| 35.42 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q04 2022 | -0.60 | -0.51 | 15.00 |
| Q03 2022 | -0.83 | -0.64 | 22.89 |
| Q02 2022 | -0.77 | -0.74 | 3.90 |
| Q01 2022 | -0.98 | -0.74 | 24.49 |
| Q04 2021 | -1.13 | -1.09 | 3.54 |
| Q03 2021 | -0.95 | -1.18 | -24.21 |
| Q02 2021 | -0.84 | -0.99 | -17.86 |
| Q01 2021 | -0.93 | -0.92 | 1.08 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 12/2022 QR | -0.60 | 21.05 | Positive |
| 12/2022 FY | -2.74 | 26.34 | Positive |
| 3/2023 QR | -0.60 | 22.08 | Positive |
| 12/2023 FY | -2.15 | 18.56 | Positive |
| Next Report Date | 11th May 2023 |
| Estimated EPS Next Report | -0.53 |
| Estimates Count | 2 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 204.46K |
| Shares Outstanding | 25.87K |
| Shares Float | 14.90M |
| Trades Count | 1.13K |
| Dollar Volume | 839.28K |
| Avg. Volume | 156.33K |
| Avg. Weekly Volume | 128.04K |
| Avg. Monthly Volume | 185.26K |
| Avg. Quarterly Volume | 155.70K |
DarioHealth Corp. (NASDAQ: DRIO) stock closed at 4.07 per share at the end of the most recent trading day (a -0.73% change compared to the prior day closing price) with a volume of 204.46K shares and market capitalization of 105.29M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 72 people. DarioHealth Corp. CEO is Erez Raphael.
The one-year performance of DarioHealth Corp. stock is -37.5%, while year-to-date (YTD) performance is -4.91%. DRIO stock has a five-year performance of -85.46%. Its 52-week range is between 3.53 and 7.6918, which gives DRIO stock a 52-week price range ratio of 12.98%
DarioHealth Corp. currently has a PE ratio of -1.30, a price-to-book (PB) ratio of 1.24, a price-to-sale (PS) ratio of 5.91, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -64.74%, a ROC of -66.86% and a ROE of -82.32%. The company’s profit margin is -%, its EBITDA margin is -248.30%, and its revenue ttm is $20.85 Million , which makes it $0.81 revenue per share.
Of the last four earnings reports from DarioHealth Corp., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.53 for the next earnings report. DarioHealth Corp.’s next earnings report date is 11th May 2023.
The consensus rating of Wall Street analysts for DarioHealth Corp. is Strong Buy (1), with a target price of $12.42, which is +205.16% compared to the current price. The earnings rating for DarioHealth Corp. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
DarioHealth Corp. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
DarioHealth Corp. has a Sell technical analysis rating based on Technical Indicators (ADX : 21.92, ATR14 : 0.36, CCI20 : -60.79, Chaikin Money Flow : -0.21, MACD : -0.23, Money Flow Index : 27.63, ROC : -17.44, RSI : 40.24, STOCH (14,3) : 17.99, STOCH RSI : 0.42, UO : 43.33, Williams %R : -82.01), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of DarioHealth Corp. in the last 12-months were: Erez Raphael (Sold 1 200 shares of value $7 449 )
DarioHealth Corp.
DarioHealth Corp is a digital health company. It is engaged in the development and commercialization of patented and proprietary technology that provides consumers with laboratory-testing capabilities using smartphones and other mobile devices. The company's product, Dario Blood sugar monitor is a mobile, real-time, cloud-based, diabetes management solution based on a multi-featured software application combined with a blood glucose monitoring device. The group operates internationally and derives revenues from the sale of its Dario smart meter and related device-specific disposables test strip cartridges and lancets. The company generates the majority of the revenue by sales of its product.
CEO: Erez Raphael
Telephone: +972 47704055
Address: 8 HaTokhen Street, Caesarea 3088900, , IL
Number of employees: 72
TipRanks News for DRIO
Tue, 14 Mar 2023 02:10 GMT Analysts Offer Insights on Healthcare Companies: DarioHealth (DRIO), Fulcrum Therapeutics (FULC) and Black Diamond Therapeutics (BDTX)
- TipRanks. All rights reserved.Mon, 13 Mar 2023 21:15 GMT DarioHealth (DRIO) Gets a Buy from LifeSci Capital
- TipRanks. All rights reserved.Fri, 10 Mar 2023 12:20 GMT Analysts Offer Insights on Healthcare Companies: DarioHealth (DRIO), Clearside Biomedical (CLSD) and Homology Medicines (FIXX)
- TipRanks. All rights reserved.Tue, 07 Feb 2023 14:40 GMT Analysts Opinions Are Mixed on These Healthcare Stocks: BioMarin Pharmaceutical (BMRN), DarioHealth (DRIO) and Evelo Biosciences (EVLO)
- TipRanks. All rights reserved.
